3.41
+0.14(+4.28%)
Currency In USD
| Previous Close | 3.27 |
| Open | 3.24 |
| Day High | 3.43 |
| Day Low | 3.17 |
| 52-Week High | 12.23 |
| 52-Week Low | 2.67 |
| Volume | 557,239 |
| Average Volume | 457,258 |
| Market Cap | 77.28M |
| PE | -3.67 |
| EPS | -0.93 |
| Moving Average 50 Days | 5.4 |
| Moving Average 200 Days | 7.83 |
| Change | 0.14 |
If you invested $1000 in Exagen Inc. (XGN) since IPO date, it would be worth $199.3 as of February 21, 2026 at a share price of $3.41. Whereas If you bought $1000 worth of Exagen Inc. (XGN) shares 5 years ago, it would be worth $192.76 as of February 21, 2026 at a share price of $3.41.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Exagen Inc. Announces Select Preliminary 2025 Financial Results
GlobeNewswire Inc.
Jan 11, 2026 8:00 PM GMT
CARLSBAD, Calif., Jan. 11, 2026 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing, today announced select preliminary unaudited financial results for the fourth quarter and year ended December 31, 2025, in line
Exagen Announces Acceptance of Six Abstracts at 2025 American College of Rheumatology Convergence
GlobeNewswire Inc.
Oct 23, 2025 1:15 PM GMT
CARLSBAD, Calif., Oct. 23, 2025 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing, announced today the acceptance of six abstracts at the 2025 American College of Rheumatology’s (ACR) annual meeting, ACR Conver
Exagen Inc. to Announce Third Quarter 2025 Financial Results on November 4, 2025
GlobeNewswire Inc.
Oct 21, 2025 8:05 PM GMT
CARLSBAD, Calif., Oct. 21, 2025 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of innovative autoimmune testing, will release financial results for the quarter ended September 30, 2025, before the market opens on Tuesday, Novembe